Navigation Links
PDL BioPharma Elects Barry Selick to Its Board of Directors
Date:8/3/2009

INCLINE VILLAGE, Nev., Aug. 3 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced the appointment of Harold E. ("Barry") Selick, Ph.D., to the Company's Board of Directors.

"Barry's experience as a seasoned biotechnology executive and his extensive knowledge of PDL's humanization technology will allow him to make valuable contributions to our strategy and operations as we seek to maximize the value of our antibody humanization patents and related assets and monetize these assets for our stockholders," said John McLaughlin, president and chief executive officer of PDL.

Dr. Selick has served as chief executive officer of Threshold Pharmaceuticals since June 2002. From January 1999 to April 2002, he was chief executive officer of biotechnology company Camitro Corporation. From 1992 to 1999, he worked at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as vice president of Research. Prior to joining Affymax, he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. As a staff scientist at Protein Design Labs, he was a co-inventor of the technology underlying the creation of fully humanized antibody therapeutics and applied this technology to PDL's first product, Zenapax (R), which was developed and commercialized by Roche for the prevention of kidney transplant rejection. Dr. Selick received his B.S. and Ph.D. from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.

About PDL BioPharma, Inc.

PDL BioPharma pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
2. PDL BioPharma Announces Second Quarter 2009 Financial Results
3. PDL BioPharma to Announce Second Quarter 2009 Financial Results and Hold Conference Call July 30, 2009
4. DOR BioPharma Appoints Christopher P. Schnittker, CPA, as Vice President of Administration and Controller
5. AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
6. Helix Biopharma Corp. Begins Trading on the OTCQX International Market Listing as HXBPF
7. Sinobiopharma Receives Trademark Approval and Authentication From Chinese Government For Its Tai Drug Series
8. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
9. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
10. PDL BioPharma Announces Record Date for October 1 Dividend Payment
11. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... February 13, 2016 , ... The producers of Enterprises ... businesses. , The increasingly modern world of instantaneous consumption proves very convenient for ... sources such as oil and coal, which pollutes our air, water, and soil. It ...
(Date:2/13/2016)... ... February 13, 2016 , ... DDi , a ... Providers list for its expertise in eClinical Solutions. DDi has built its solution ... technology needs of global clients. DDi provides smarter technology for Clinical Development, Regulatory ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... philanthropic community at its 10th anniversary Fashion Luncheon on Monday, February 8, 2016. ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Coco Libre, the ... in Red Carpet Events LA GRAMMY’s Style Lounge Event. Coco Libre will offer musicians ... stay hydrated before the big event. The invitation-only gifting suite, held this year at ...
(Date:2/12/2016)... Las Vegas, NV (PRWEB) , ... February 12, 2016 , ... ... of North Las Vegas Mayor John J. Lee, Nevada Military Support Alliance president Scott ... newest Fisher House at the VA Southern Nevada Healthcare System. This will be ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... and SEOUL, South Korea , ... and Macrogen, Inc. today announced they will form ... procedures for precision medicine in cancer. The goal ... DEPArray™ digital-sorting technology with Macrogen,s high-throughput Next Generation ... under the Clinical Laboratory Improvement Amendments (CLIA) of ...
(Date:2/12/2016)... Feb. 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ... the Company will ring the Nasdaq Closing Bell at ... York at 4:00 p.m. ET on Tuesday, ... Adrian Adams , will perform the ... to 4:00 p.m. ET.  A live webcast will be ...
(Date:2/12/2016)... Carolina , 12 februari 2016 /PRNewswire/ ... (AAI/CML), een toonaangevende leverancier van productie en ... biotechnologische industrieën, kondigt vandaag een uitbreiding aan ... op haar locatie in Charleston, ... heeft geleid tot meerdere recente investeringen. ...
Breaking Medicine Technology: